FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of this study is to evaluate in Chronic Kidney Disease (CKD) patients not on dialysis and who have an Fibroblast growth factor 23 (FGF23) serum levels elevated, the effect of non calcic phosphate binder: sevelamer carbonate. This treatment could lead to a diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary phosphate. In addition, the investigators will describe the impact of the FGF23 level monitoring on the main phosphocalcium metabolism markers as phosphatemia, intact parathyroid hormone (iPTH), serum calcitriol and phosphaturia.
Epistemonikos ID: 6882379ab6db664d9ce0f9b5b9664ba8eae7f4ea
First added on: May 06, 2024